For example, in 2005, Hartung et al39 found that patients with congestive heart failure (CHF) on their problem list were more likely to receive angiotensin-converting enzyme inhibitors or angiotensin-II receptor blockers than for those CHF patients without CHF listed on their problem list. The gene discussed is ACE; the disease is congestive heart failure.